Skip to main content

Peer Review reports

From: Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status

Original Submission
27 Jun 2024 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
18 Jul 2024 Author responded Author comments - Yoshihiko Taniguchi
Resubmission - Version 3
18 Jul 2024 Submitted Manuscript version 3
18 Jul 2024 Author responded Author comments - Yoshihiko Taniguchi
Resubmission - Version 4
18 Jul 2024 Submitted Manuscript version 4
21 Jul 2024 Reviewed Reviewer Report - Savvas Lampridis
25 Jul 2024 Reviewed Reviewer Report
2 Aug 2024 Author responded Author comments - Yoshihiko Taniguchi
Resubmission - Version 5
2 Aug 2024 Submitted Manuscript version 5
Publishing
9 Aug 2024 Editorially accepted
24 Aug 2024 Article published 10.1186/s12890-024-03212-5

You can find further information about peer review here.

Back to article page